WO2008108386A1 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
WO2008108386A1
WO2008108386A1 PCT/JP2008/053908 JP2008053908W WO2008108386A1 WO 2008108386 A1 WO2008108386 A1 WO 2008108386A1 JP 2008053908 W JP2008053908 W JP 2008053908W WO 2008108386 A1 WO2008108386 A1 WO 2008108386A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
hydrogen atom
lower alkyl
unsubstituted lower
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053908
Other languages
English (en)
French (fr)
Inventor
Shiro Soga
Toshihiko Ishii
Takayuki Nakashima
Yukimasa Shiotsu
Shiro Akinaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to CA002680161A priority Critical patent/CA2680161A1/en
Priority to US12/529,380 priority patent/US20100098690A1/en
Priority to CN2008800071743A priority patent/CN101641117B/zh
Priority to JP2009502597A priority patent/JPWO2008108386A1/ja
Priority to EP08721328A priority patent/EP2133094A4/en
Publication of WO2008108386A1 publication Critical patent/WO2008108386A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　Hsp90ファミリー蛋白質阻害剤と、少なくとも1つの化合物とを組み合わせてなる医薬組成物、該Hsp90ファミリー蛋白質阻害剤が式(I) ［式中、nは1～5の整数を表し、R1は置換もしくは非置換の低級アルキル、CONR7R8（式中、R7及びR8は同一または異なって、水素原子、置換もしくは非置換の低級アルキル等を表す）等を表し、R2は置換もしくは非置換のアリール等を表し、R3及びR5は同一または異なって、水素原子、置換もしくは非置換の低級アルキル等を表し、R4は水素原子、ヒドロキシまたはハロゲンを表し、R6は水素原子、ハロゲン、置換もしくは非置換の低級アルキル等を表す]で表されるベンゾイル化合物もしくはそのプロドラッグまたはその薬理学的に許容される塩である前記医薬組成物等を提供する。 　
PCT/JP2008/053908 2007-03-05 2008-03-05 医薬組成物 Ceased WO2008108386A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002680161A CA2680161A1 (en) 2007-03-05 2008-03-05 Pharmaceutical composition
US12/529,380 US20100098690A1 (en) 2007-03-05 2008-03-05 Pharmaceutical composition
CN2008800071743A CN101641117B (zh) 2007-03-05 2008-03-05 药物组合物
JP2009502597A JPWO2008108386A1 (ja) 2007-03-05 2008-03-05 医薬組成物
EP08721328A EP2133094A4 (en) 2007-03-05 2008-03-05 PHARMACEUTICAL COMPOSITION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-053675 2007-03-05
JP2007053675 2007-03-05

Publications (1)

Publication Number Publication Date
WO2008108386A1 true WO2008108386A1 (ja) 2008-09-12

Family

ID=39738259

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053908 Ceased WO2008108386A1 (ja) 2007-03-05 2008-03-05 医薬組成物

Country Status (8)

Country Link
US (1) US20100098690A1 (ja)
EP (2) EP2133094A4 (ja)
JP (2) JPWO2008108386A1 (ja)
KR (1) KR20090116794A (ja)
CN (1) CN101641117B (ja)
CA (1) CA2680161A1 (ja)
TW (1) TW200901960A (ja)
WO (1) WO2008108386A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011049946A1 (en) * 2009-10-19 2011-04-28 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
JP2017505777A (ja) * 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
JP2017507150A (ja) * 2014-03-03 2017-03-16 シンタ ファーマスーティカルズ コーポレイションＳｙｎｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 標的治療薬
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
WO2025041853A1 (ja) * 2023-08-24 2025-02-27 大鵬薬品工業株式会社 アザ二環式化合物と抗アンドロゲン剤を用いたがん併用療法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CN101316590B (zh) 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
JP2013525292A (ja) * 2010-04-16 2013-06-20 ノバルティス アーゲー 有機化合物の組合せ
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2678013A1 (en) * 2011-02-23 2014-01-01 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3131586A4 (en) 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
JP2020524156A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬を含む併用療法
JP2020524154A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2005000778A1 (ja) 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005012257A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. インダゾール誘導体
WO2005012258A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2005063222A1 (ja) 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2005112952A2 (en) * 2004-05-20 2005-12-01 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006010595A1 (en) * 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
WO2006088193A1 (ja) 2005-02-21 2006-08-24 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539273A (ja) * 2005-04-29 2008-11-13 コーザン バイオサイエンシス インコーポレイテッド １７−ａａｇ又は１７−ａｇ又はどちらかのプロドラッグをプロテアソーム阻害剤と組み合わせて使用する多発性骨髄腫の治療方法
EP2133095A4 (en) * 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
JPWO2009028387A1 (ja) * 2007-08-24 2010-12-02 協和発酵キリン株式会社 プロテアーゼ阻害剤耐性を有する癌の治療薬

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036075A2 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003055860A1 (en) 2001-12-21 2003-07-10 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
WO2005000778A1 (ja) 2003-06-27 2005-01-06 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005012257A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. インダゾール誘導体
WO2005012258A1 (ja) 2003-07-30 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. タンパク質キナーゼ阻害剤
WO2005063222A1 (ja) 2003-12-26 2005-07-14 Kyowa Hakko Kogyo Co., Ltd. Hsp90ファミリー蛋白質阻害剤
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2005095341A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 含窒素複素環化合物
WO2005112952A2 (en) * 2004-05-20 2005-12-01 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
WO2006010595A1 (en) * 2004-07-27 2006-02-02 Novartis Ag Inhibitors of hsp90
WO2006088193A1 (ja) 2005-02-21 2006-08-24 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"International Journal of Radiation Oncology", BIOLOGY, PHYSICS, vol. 5, 1979, pages 85
"International Journal of Radiation Oncology", BIOLOGY, PHYSICS, vol. 5, 1979, pages 85 - 91
ADVANCES IN DRUG RES., vol. 13, 1984, pages 224 - 331
BIOCHEM. PHARMACOL, vol. 56, 1998, pages 675 - 682
BLOOD, vol. 107, 2006, pages 1092 - 1100
BLOOD, vol. 96, 2000, pages 2284 - 2291
BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER PRESS
CANCER CHEMOTHER. PHARMACOL., vol. 48, 2001, pages 435 - 445
CANCER RES., vol. 59, 1999, pages 2931 - 2938
CANCER RES., vol. 63, 2003, pages 2139 - 2144
CANCER RES., vol. 66, 2006, pages 1089 - 1095
CELL STRESS CHAPERONES, vol. 3, 1998, pages 100 - 108
CELL, vol. 89, 1997, pages 239 - 250
CLIN. CANCER RES., vol. 10, 2004, pages 8077 - 8084
CLIN. CANCER RES., vol. 12, 2006, pages 584 - 590
CLIN. CANCER RES., vol. 12, 2006, pages 6547 - 6556
CLIN. CANCER RES., vol. 9, 2003, pages 3749 - 3755
CURRENT MEDICINAL CHEMISTRY, vol. 14, 2007, pages 223 - 232
DRUG DEV. RES., vol. 34, 1995, pages 220 - 230
EMBO JOURNAL, vol. 21, 2002, pages 2407 - 2417
EXPERT OPINION ON BIOLOGICAL THERAPY, vol. 2, 2002, pages 3 - 24
IBID., vol. 5, 1979, pages 1145
INVEST. NEW DRUGS, vol. 17, 1999, pages 361 - 373
J. MED. CHEM., vol. 40, 1997, pages 2011 - 2016
J. MED. CHEM., vol. 42, 1999, pages 260 - 266
J. NATL. CANCER INST., vol. 92, 2000, pages 242 - 248
LEUKEMIA, vol. 20, 2006, pages 610 - 619
MERCK MANUAL, 10 December 1999 (1999-12-10), pages 983 - 992 *
MOL. CANCER THER., vol. 3, 2004, pages 551 - 566
MOL. CANCER THR., vol. 5, 2006, pages 1197 - 1208
MOL. CANCER THR., vol. 5, 2006, pages 179 - 186
NVEST. NEW DRUGS, vol. 17, 1999, pages 361 - 373
PHARMACOL. THER., vol. 79, 1997, pages 129 - 168
See also references of EP2133094A4 *
T.W. GREENE: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS INC.

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013508378A (ja) * 2009-10-19 2013-03-07 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物を用いる併用がん療法
EA022119B1 (ru) * 2009-10-19 2015-11-30 Синта Фармасьютиклз Корп. Комбинированная терапия раковых заболеваний с помощью соединений - ингибиторов hsp90
WO2011049946A1 (en) * 2009-10-19 2011-04-28 Synta Pharmaceuticals Corp. Combination cancer therapy with hsp90 inhibitory compounds
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
US10500193B2 (en) 2011-11-02 2019-12-10 Synta Pharmaceuticals Corporation Combination therapy of HSP90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
JP2017505777A (ja) * 2014-01-29 2017-02-23 シンタ ファーマスーティカルズ コーポレーション 標的化治療薬
US10232049B2 (en) 2014-03-03 2019-03-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP2019196406A (ja) * 2014-03-03 2019-11-14 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
JP2017507150A (ja) * 2014-03-03 2017-03-16 シンタ ファーマスーティカルズ コーポレイションＳｙｎｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 標的治療薬
US10675360B2 (en) 2014-03-03 2020-06-09 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2025041853A1 (ja) * 2023-08-24 2025-02-27 大鵬薬品工業株式会社 アザ二環式化合物と抗アンドロゲン剤を用いたがん併用療法

Also Published As

Publication number Publication date
JPWO2008108386A1 (ja) 2010-06-17
CA2680161A1 (en) 2008-09-12
CN101641117B (zh) 2012-06-13
US20100098690A1 (en) 2010-04-22
CN101641117A (zh) 2010-02-03
TW200901960A (en) 2009-01-16
JP2013121987A (ja) 2013-06-20
KR20090116794A (ko) 2009-11-11
EP2543390A1 (en) 2013-01-09
EP2133094A1 (en) 2009-12-16
EP2133094A4 (en) 2010-10-13

Similar Documents

Publication Publication Date Title
WO2008111441A1 (ja) 医薬組成物
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MY148703A (en) Polycyclic cinnamide derivatives
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
WO2009069736A1 (ja) 含窒素化合物
MX2010002098A (es) Compuesto policiclico.
TW200612958A (en) Substituted imidazole derivatives
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
EP1798226A4 (en) TRAIZOL DERIVATIVE
WO2007126900A3 (en) Antifungal agents
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2007031933A3 (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MX2008002061A (es) Derivados de tiazolil piperidina utiles como moduladores del receptor h3.
WO2008105526A1 (ja) マクロ環状化合物
TW200745032A (en) Novel heterobicyclic derivatives
MX2010001566A (es) Derivado de aminopirazolamida.
TW200612920A (en) Novel imidazolidine derivatives
WO2009028387A1 (ja) プロテアーゼ阻害剤耐性を有する癌の治療薬
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2008145524A3 (en) 4,4-disubstituted piperidine derivatives
MX2010010471A (es) Derivado de tetrahidroisoquinolina novedoso.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880007174.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721328

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12529380

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2009502597

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2680161

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020097019162

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008721328

Country of ref document: EP